Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

By Rene Pretorius

April 21, 2025

Summary

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a Phase 3 trial. It showed significant efficacy, lowering A1C levels by 1.3% to 1.6% and achieving weight loss of up to 16 pounds. The drug’s safety profile matched injectable GLP-1 medications, with common gastrointestinal side effects. Orforglipron is the first oral small molecule GLP-1 receptor agonist to finish Phase 3, offering a convenient option for type 2 diabetes and obesity.

Key Insights

  • Efficacy: Orforglipron reduced A1C levels and induced weight loss. Over 65% of participants on the highest dose achieved an A1C below 6.5%.
  • Safety Profile: The drug’s safety was similar to injectable GLP-1 therapies, with mild to moderate gastrointestinal side effects.
  • Innovation: As a small molecule, orforglipron may be easier to produce and scale up than peptide-based GLP-1 agonists.

The Oral GLP-1 Medication Market

Type 2 diabetes may affect 760 million adults by 2050, increasing demand for effective treatments. GLP-1 receptor agonists help with glucose control and weight management, but most require injections, which can reduce compliance. Oral GLP-1 medication like orforglipron could improve adherence. The World Health Organization supports innovative treatments for chronic diseases, aligning with Lilly’s mission.

Implications

Orforglipron’s Phase 3 success has key implications:

  • Accessibility and Cost: A once-daily pill could lower costs and improve adherence compared to injectables.
  • Market Impact: Projected sales of $11.8 billion by 2030 could boost the GLP-1RA market.
  • Healthcare Implications: Innovative treatments may improve chronic disease management, reducing long-term costs and enhancing quality of life.

For more details, visit here.

Reference url

Recent Posts

Building a Better Ecosystem for Digitally Enabled Diabetes Care in Europe

By João L. Carapinha

August 8, 2025

Digitally enabled diabetes care is rapidly transforming the management of Type 2 diabetes (T2D) across Europe. How does expanding access to these digital solutions improve health outcomes and reduce costs for individuals and health systems? Early evidence and recent policy recommendations (publis...
NICE’s 2025 Guidance on Obesity Management Support

By João L. Carapinha

August 6, 2025

NICE’s August 2025 quality standard on obesity management support emphasizes the need for sustained support after weight management interventions. The guidance formalizes specific expectations for recording, support, and follow-up. It targets adults, children, and key groups like people with long...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...